Figure adapted from Martinez-Marti et al. ESMO 2021 oral presentation (LBA42).
- Overview
- Clinical Trials
- Abbreviations
Target Overview
CD73, or ecto-5’-nucleotidase, is a cell surface enzyme expressed on tumor cells, endothelial cells, lymphoid cells, and myeloid cells, including antigen-presenting cells.1 It catalyzes the conversion of extracellular AMP to the nucleoside adenosine.1,2
Overexpression of CD73 and elevated extracellular levels of adenosine in the microenvironments of many solid tumors are known to exert potent immunosuppressive effects by binding of adenosine to adenosine receptors on antigen-presenting cells and lymphocytes, including T cells.1,2 This is known to suppress many aspects of antitumor immunity.
Compound Overview
Oleclumab is an investigational human IgG1λ monoclonal antibody that selectively binds to and inhibits the ectonucleotidase activity of CD73. Results from preclinical studies suggest that oleclumab may help to overcome adenosine-mediated immunosuppression in a number of solid tumor model systems. The molecule is currently being clinically evaluated in solid tumor malignancies.
Mechanism of Action
References
1. Vijayan D, Young A, Teng MWL, et al. Nat Rev Cancer. 2017;17(12):709-724. 2. Vigano S, Alatzoglou D, Irving M, et al. Front Immunol. 2019;10:925.
Clinical trial information
Select trial for more information
Arrange By
Selected Filter(s)
Abbreviations
1L
first line
ADP
adenosine diphosphate
ALK
anaplastic lymphoma kinase
AMP
adenosine monophosphate
ATP
adenosine triphosphate
BICR
blinded independent central review
cCRT
concurrent chemoradiation therapy
CD73
cluster of differentiation 73
DoR
duration of response
EGFR
epidermal growth factor receptor
FOLFOX
folinic acid (leucovorin), fluorouracil (5-FU), oxaliplatin
IgG1
immunoglobulin G1
IV
intravenous
mCRPC
metastatic castration-resistant prostate cancer
MSS-CRC
microsatellite stable colorectal cancer
NSCLC
non-small cell lung cancer
ORR
overall or objective response rate
OS
overall survival
P2X7
P2X purinoceptor 7
P2Y2
P2Y purinoceptor 2
PD-L1
programmed cell death ligand-1
PDC
platinum doublet chemotherapy
PFS
progression-free survival
PFS2
time to second progression or death
Q*W
every * weeks
Q4W
every 4 weeks
R
randomization
RECIST
Response Evaluation Criteria in Solid Tumors
TFST
time to first subsequent therapy
TTDM
time to death or distant metastases
Target Overview
CD73, or ecto-5’-nucleotidase, is a cell surface enzyme expressed on tumor cells, endothelial cells, lymphoid cells, and myeloid cells, including antigen-presenting cells.1 It catalyzes the conversion of extracellular AMP to the nucleoside adenosine.1,2
Overexpression of CD73 and elevated extracellular levels of adenosine in the microenvironments of many solid tumors are known to exert potent immunosuppressive effects by binding of adenosine to adenosine receptors on antigen-presenting cells and lymphocytes, including T cells.1,2 This is known to suppress many aspects of antitumor immunity.
Compound Overview
Oleclumab is an investigational human IgG1λ monoclonal antibody that selectively binds to and inhibits the ectonucleotidase activity of CD73. Results from preclinical studies suggest that oleclumab may help to overcome adenosine-mediated immunosuppression in a number of solid tumor model systems. The molecule is currently being clinically evaluated in solid tumor malignancies.
Mechanism of Action
Figure adapted from Martinez-Marti et al. ESMO 2021 oral presentation (LBA42).
References
1. Vijayan D, Young A, Teng MWL, et al. Nat Rev Cancer. 2017;17(12):709-724. 2. Vigano S, Alatzoglou D, Irving M, et al. Front Immunol. 2019;10:925.
Clinical trial information
Select trial for more information
Arrange By
Selected Filter(s)
Abbreviations
1L
first line
ADP
adenosine diphosphate
ALK
anaplastic lymphoma kinase
AMP
adenosine monophosphate
ATP
adenosine triphosphate
BICR
blinded independent central review
cCRT
concurrent chemoradiation therapy
CD73
cluster of differentiation 73
DoR
duration of response
EGFR
epidermal growth factor receptor
FOLFOX
folinic acid (leucovorin), fluorouracil (5-FU), oxaliplatin
IgG1
immunoglobulin G1
IV
intravenous
mCRPC
metastatic castration-resistant prostate cancer
MSS-CRC
microsatellite stable colorectal cancer
NSCLC
non-small cell lung cancer
ORR
overall or objective response rate
OS
overall survival
P2X7
P2X purinoceptor 7
P2Y2
P2Y purinoceptor 2
PD-L1
programmed cell death ligand-1
PDC
platinum doublet chemotherapy
PFS
progression-free survival
PFS2
time to second progression or death
Q*W
every * weeks
Q4W
every 4 weeks
R
randomization
RECIST
Response Evaluation Criteria in Solid Tumors
TFST
time to first subsequent therapy
TTDM
time to death or distant metastases